Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

121 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Risk Factors for Steroid-Refractory Acute Graft-versus-Host Disease after Allogeneic Stem Cell Transplantation from Matched Related or Unrelated Donors.
Calmettes C, Vigouroux S, Labopin M, Tabrizi R, Turlure P, Lafarge X, Marit G, Pigneux A, Leguay T, Bouabdallah K, Dilhuydy MS, Duclos C, Mohr C, Lascaux A, Dumas PY, Dimicoli-Salazar S, Saint-Lézer A, Milpied N. Calmettes C, et al. Among authors: vigouroux s. Biol Blood Marrow Transplant. 2015 May;21(5):860-5. doi: 10.1016/j.bbmt.2015.01.016. Epub 2015 Jan 21. Biol Blood Marrow Transplant. 2015. PMID: 25617807 Free article.
Methotrexate Reduces the Incidence of Severe Acute Graft-versus-Host Disease without Increasing the Risk of Relapse after Reduced-Intensity Allogeneic Stem Cell Transplantation from Unrelated Donors.
Vigouroux S, Tabrizi R, Melot C, Coiffard J, Lafarge X, Marit G, Bouabdallah K, Pigneux A, Leguay T, Dilhuydy MS, Schmitt A, Boiron JM, Milpied N. Vigouroux S, et al. Biol Blood Marrow Transplant. 2011 Jan;17(1):93-100. doi: 10.1016/j.bbmt.2010.06.013. Epub 2010 Jun 19. Biol Blood Marrow Transplant. 2011. PMID: 20601038 Free article.
Potent graft-versus-leukemia effect after reduced-intensity allogeneic SCT for intermediate-risk AML with FLT3-ITD or wild-type NPM1 and CEBPA without FLT3-ITD.
Labouré G, Dulucq S, Labopin M, Tabrizi R, Guérin E, Pigneux A, Lafarge X, Leguay T, Bouabdallah K, Dilhuydy MS, Duclos C, Lascaux A, Marit G, Mahon FX, Boiron JM, Milpied N, Vigouroux S. Labouré G, et al. Among authors: vigouroux s. Biol Blood Marrow Transplant. 2012 Dec;18(12):1845-50. doi: 10.1016/j.bbmt.2012.06.012. Epub 2012 Jul 2. Biol Blood Marrow Transplant. 2012. PMID: 22766221 Free article.
Transient grades 3 to 4 acute hepatitis is a common complication of rabbit antithymocyte globulin (thymoglobulin) administered before allogeneic stem cell transplantation.
Médiavilla C, Vigouroux S, Tabrizi R, Pigneux A, Duclos C, Mohr C, Robles M, Milpied N. Médiavilla C, et al. Among authors: vigouroux s. Biol Blood Marrow Transplant. 2015 Apr;21(4):661-5. doi: 10.1016/j.bbmt.2014.12.014. Epub 2014 Dec 20. Biol Blood Marrow Transplant. 2015. PMID: 25536216 Free article.
Influence of Previous Inflammatory Bowel Disease on the Outcome of Allogeneic Hematopoietic Stem Cell Transplantation: A Matched-Pair Analysis.
Rabian F, Porcher R, Sicre de Fontbrune F, Lioure B, Laplace A, Nguyen S, Tabrizi R, Vigouroux S, Tomowiak C, Maillard N, Suarez F, Delage J, Peffault de Latour R, Socié G; French Society of Bone Marrow Transplantation and Cell Therapy. Rabian F, et al. Among authors: vigouroux s. Biol Blood Marrow Transplant. 2016 Sep;22(9):1721-1724. doi: 10.1016/j.bbmt.2016.05.022. Epub 2016 May 28. Biol Blood Marrow Transplant. 2016. PMID: 27246370 Free article.
Prospective phase II study of prophylactic low-dose azacitidine and donor lymphocyte infusions following allogeneic hematopoietic stem cell transplantation for high-risk acute myeloid leukemia and myelodysplastic syndrome.
Guillaume T, Malard F, Magro L, Labopin M, Tabrizi R, Borel C, Chevallier P, Vigouroux S, Peterlin P, Garnier A, Rubio MT, Huynh A, Milpied N, Moreau P, Gaugler B, Yakoub-Agha I, Mohty M. Guillaume T, et al. Among authors: vigouroux s. Bone Marrow Transplant. 2019 Nov;54(11):1815-1826. doi: 10.1038/s41409-019-0536-y. Epub 2019 May 14. Bone Marrow Transplant. 2019. PMID: 31089280 Clinical Trial.
Allogeneic SCT for patients with high-risk peripheral T-cell lymphoma in first response.
Robles M, Vigouroux S, Tabrizi R, Bouabdallah K, Dilhuydy MS, Parrens M, Leguay T, Pigneux A, Dumas PY, Lascaux A, Duclos C, Marit G, Milpied N. Robles M, et al. Among authors: vigouroux s. Bone Marrow Transplant. 2013 Nov;48(11):1484-5. doi: 10.1038/bmt.2013.86. Epub 2013 Jun 3. Bone Marrow Transplant. 2013. PMID: 23727750 No abstract available.
Long-term outcomes after reduced-intensity conditioning allogeneic stem cell transplantation for low-grade lymphoma: a survey by the French Society of Bone Marrow Graft Transplantation and Cellular Therapy (SFGM-TC).
Vigouroux S, Michallet M, Porcher R, Attal M, Ades L, Bernard M, Blaise D, Tabrizi R, Garban F, Cassuto JP, Chevalier P, Facon T, Ifrah N, Renaud M, Tilly H, Vernant JP, Kuentz M, Bourhis JH, Bordigoni P, Deconinck E, Lioure B, Socié G, Milpied N; French Society of Bone Marrow Graft Transplantation and Cellular Therapy (SFGM-TC). Vigouroux S, et al. Haematologica. 2007 May;92(5):627-34. doi: 10.3324/haematol.10924. Haematologica. 2007. PMID: 17488686 Free article.
Comparable outcome after related or unrelated allogeneic stem cell transplant following reduced conditioning with fludarabine, busulfan and antithymocyte globulin.
Vigouroux S, Tabrizi R, Melot C, Coiffard J, Lafarge X, Marit G, Bouabdallah K, Pigneux A, Leguay T, Dilhuydy MS, Schmitt A, Boiron JM, Milpied N. Vigouroux S, et al. Leuk Lymphoma. 2012 Jan;53(1):162-5. doi: 10.3109/10428194.2011.604754. Epub 2011 Aug 18. Leuk Lymphoma. 2012. PMID: 21756024 No abstract available.
121 results